Pregled bibliografske jedinice broj: 1206033
Exclusion of relevant concentrations of direct oral anticoagulants in blood by DOAC Dipstick – proposal of a diagnostic algorithm for improvement of clinical decision-making in emergencies
Exclusion of relevant concentrations of direct oral anticoagulants in blood by DOAC Dipstick – proposal of a diagnostic algorithm for improvement of clinical decision-making in emergencies // Research and Practice in Thrombosis and Haemostasis / Cushman, Mary (ur.).
Medford: Willey Online, 2022. PB1064, 1 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 1206033 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Exclusion of relevant concentrations of direct oral anticoagulants in blood by DOAC Dipstick – proposal of a diagnostic algorithm for improvement of clinical decision-making in emergencies
Autori
Ćelap, Ivana ; Margetić, Sandra ; Periša, Josipa ; Razum, Marija ; Šupraha-Goreta, Sandra ; Čajević-Glojnarić, Anesa
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Research and Practice in Thrombosis and Haemostasis
/ Cushman, Mary - Medford : Willey Online, 2022
Skup
30th Congress of the International Society on Thrombosis and Haemostasis (ISTH2022)
Mjesto i datum
London, Ujedinjeno Kraljevstvo, 09.07.2022. - 13.07.2022
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
DOACs, urine sample
Sažetak
Background: Rapid and accurate determination of direct oral anticoagulants (DOACs) is still a major medical need in urgent clinical situations. Aims: The aim of this study was to identify the feasibility of algorithm for rapid exclusion of clinically significant concentration of DOACs (>30 ng/mL) by data from in patients from cardiology and neurology departments. Methods: The study included 128 paired plasma and urine samples from patients treated for non-valvular atrial fibrillation of venous thromboembolism with an oral direct factor Xa inhibitor (DXI) (apixaban, n=31, rivaroxaban, n=53) and direct thrombin inhibitor (DTI) (dabigatran, n=44) at trough drug levels. Plasma DOACs concentrations were determined by quantitative chromogenic substrate assays (Innovance anti-FXa assay for rivaroxaban and apixaban and Innovance DTI assay for dabigatran) on BCSXP analyzer (Siemens Healthineers, Germany). Urine samples were evaluated by DOAC Dipstick test (DOASENSE GmbH, Heidelberg, Germany) to determine the presence or absence of DOACs. Parameters of diagnostic accuracy were determined by receiver operating curve (ROC) analysis. Comparison between DOAC Dipstick test results and plasma concentrations of DOACs were obtained using kappa statistics. The study was funded as a part of Croatian Science Foundation research project IP-2016-06-8208. Results: ROC analysis revealed threshold values of plasma concentrations for DXI ≥14 ng/mL and ≥19 ng/mL for DTI for detection of DXI and DTI by DOAC Dipstick, respectively. At cut-off value ≥19 ng/mL for DTI there was no false negative or false positive results (kappa value=1.0). For DXI at cut-off ≥14 ng/mL one false positive result was obtained, κ=0.92 (95 % CI 0.74-1.00). Conclusion(s): Application of an algorithm for exclusion of relevant plasma concentrations by DOAC Dipstick can be proposed by testing first DOACs in urine and if positive followed by quantitative DOAC assays if clinically required.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti, Farmacija
POVEZANOST RADA
Projekti:
IP-2016-06-8208 - Novi oralni antikoagulansi: povezanost koncentracije lijeka i antikoagulantnog učinka (LAB-NOAC) (Margetić, Sandra, HRZZ - 2016-06) ( CroRIS)
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
KBC "Sestre Milosrdnice",
Hrvatsko katoličko sveučilište, Zagreb
Profili:
Josipa Periša
(autor)
Sandra Šupraha Goreta
(autor)
Ivana Ćelap
(autor)
Sandra Margetić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Emerging Sources Citation Index (ESCI)
- Scopus